Optimal Therapy for Early-Stage Hodgkin’s Lymphoma: Risk Adapting, Response Adapting, and Role of Radiotherapy

[1] Pusey WA(1902)Cases of sarcoma and Hodgkin’s disease treated by exposure to X-rays: a preliminary report JAMA XXXVIII 166-169

[2] Gilbert R(1939)Radiotherapy in Hodgkin’s disease (malignant granulomatosis): anatomic and clinical foundations; governing principles; results Nucl Med 41 198-241

[3] Peters MV(1950)A study of survivals in Hodgkin’s disease treated radiologically Am J Roentgenol Radium Therapy, Nucl Med 63 299-311

[4] Engert A(2003)Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin’s lymphoma: results of the HD8 trial of the German Hodgkin’s Lymphoma Study Group J Clin Oncol 21 3601-3608

[5] Schiller P(2010)Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group HD11 trial J Clin Oncol 28 4199-4206

[6] Josting A(2016)Current developments in the treatment of early stage classical Hodgkin lymphoma Curr Opin Oncol 28 377-383

[7] Eich HT(2016)Tretament of early stage Hodgkin lymphoma Semin Hematol 53 165-170

[8] Diehl V(2015)Early-stage classic Hodgkin lymphoma: the utilization of radiation therapy and its impact on overall survival Int J Radiat Oncol Biol Phys 93 684-693

[9] Görgen H(2015)The concept and evolution of involved site radiotherapy for lymphoma Int J Clin Oncol 20 849-854

[10] Borchmann S(2007)Early interim 2-[18F]Fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian-Danish study J Clin Oncol 25 3746-3752

[1] Pusey WA(1902)Cases of sarcoma and Hodgkin’s disease treated by exposure to X-rays: a preliminary report JAMA XXXVIII 166-169

[2] Gilbert R(1939)Radiotherapy in Hodgkin’s disease (malignant granulomatosis): anatomic and clinical foundations; governing principles; results Nucl Med 41 198-241

[3] Peters MV(1950)A study of survivals in Hodgkin’s disease treated radiologically Am J Roentgenol Radium Therapy, Nucl Med 63 299-311

[4] Engert A(2003)Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin’s lymphoma: results of the HD8 trial of the German Hodgkin’s Lymphoma Study Group J Clin Oncol 21 3601-3608

[5] Schiller P(2010)Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group HD11 trial J Clin Oncol 28 4199-4206

[6] Josting A(2016)Current developments in the treatment of early stage classical Hodgkin lymphoma Curr Opin Oncol 28 377-383

[7] Eich HT(2016)Tretament of early stage Hodgkin lymphoma Semin Hematol 53 165-170

[8] Diehl V(2015)Early-stage classic Hodgkin lymphoma: the utilization of radiation therapy and its impact on overall survival Int J Radiat Oncol Biol Phys 93 684-693

[9] Görgen H(2015)The concept and evolution of involved site radiotherapy for lymphoma Int J Clin Oncol 20 849-854

[10] Borchmann S(2007)Early interim 2-[18F]Fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian-Danish study J Clin Oncol 25 3746-3752